Hartmut Koeppen

8.6k total citations · 2 hit papers
62 papers, 6.4k citations indexed

About

Hartmut Koeppen is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Hartmut Koeppen has authored 62 papers receiving a total of 6.4k indexed citations (citations by other indexed papers that have themselves been cited), including 41 papers in Oncology, 16 papers in Molecular Biology and 16 papers in Immunology. Recurrent topics in Hartmut Koeppen's work include Cancer Immunotherapy and Biomarkers (15 papers), Immunotherapy and Immune Responses (10 papers) and CAR-T cell therapy research (8 papers). Hartmut Koeppen is often cited by papers focused on Cancer Immunotherapy and Biomarkers (15 papers), Immunotherapy and Immune Responses (10 papers) and CAR-T cell therapy research (8 papers). Hartmut Koeppen collaborates with scholars based in United States, France and South Korea. Hartmut Koeppen's co-authors include Ralph Schwall, Avi Ashkenazi, Scot A. Marsters, Sharon Fong, Hans Schreiber, David A. Lawrence, Laura DeForge, Andrea Hebert, Iphigenia L. Koumenis and Ling Chang and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Investigation and Nature Communications.

In The Last Decade

Hartmut Koeppen

60 papers receiving 6.3k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Safety and antitumor activity of recombinant soluble Apo2 ligand

1999 1.9k citations Avi Ashkenazi, Scot A. Marsters et al. profile →
Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody–Cytotoxic Drug Conjugate

2008 1.3k citations Gail D. Lewis Phillips, Guangmin Li et al. Cancer Research profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Hartmut Koeppen United States	30	3.5k	3.0k	1.9k	1.2k	992	62	6.4k
Helena J. Mauceri United States	34	3.2k 0.9×	2.6k 0.9×	2.2k 1.2×	632 0.5×	1.4k 1.4×	74	6.6k
Patrizia Nanni Italy	48	2.8k 0.8×	2.5k 0.8×	2.6k 1.4×	910 0.8×	813 0.8×	171	6.5k
Uwe Zangemeister‐Wittke Switzerland	44	4.0k 1.1×	1.6k 0.5×	1.0k 0.6×	866 0.7×	662 0.7×	108	5.6k
Henrik J. Ditzel Denmark	48	3.7k 1.0×	1.9k 0.6×	2.0k 1.1×	1.1k 0.9×	1.6k 1.6×	214	7.1k
Takuya Osada United States	42	2.7k 0.8×	2.0k 0.7×	2.1k 1.1×	530 0.4×	1.1k 1.1×	117	5.5k
Toshihiko Torigoe Japan	50	4.3k 1.2×	3.7k 1.2×	3.6k 1.9×	448 0.4×	1.1k 1.2×	348	8.5k
Olivier Gires Germany	42	2.8k 0.8×	3.4k 1.1×	1.3k 0.7×	462 0.4×	1.3k 1.3×	109	6.2k
Carla De Giovanni Italy	39	2.1k 0.6×	1.8k 0.6×	2.0k 1.1×	677 0.6×	597 0.6×	149	4.7k
Andrea Anichini Italy	50	3.3k 0.9×	3.3k 1.1×	4.4k 2.4×	567 0.5×	611 0.6×	198	7.9k
Serenella M. Pupa Italy	35	2.3k 0.6×	2.3k 0.8×	1.5k 0.8×	1.4k 1.2×	833 0.8×	94	4.8k

Countries citing papers authored by Hartmut Koeppen

Since Specialization

Citations

This map shows the geographic impact of Hartmut Koeppen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hartmut Koeppen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hartmut Koeppen more than expected).

Fields of papers citing papers by Hartmut Koeppen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hartmut Koeppen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hartmut Koeppen. The network helps show where Hartmut Koeppen may publish in the future.

Co-authorship network of co-authors of Hartmut Koeppen

This figure shows the co-authorship network connecting the top 25 collaborators of Hartmut Koeppen. A scholar is included among the top collaborators of Hartmut Koeppen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hartmut Koeppen. Hartmut Koeppen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Rini, Brian I., Laurence Albigès, Xiaobin Tang, et al.. (2025). Circulating kidney injury molecule-1 (KIM-1) and association with outcome to adjuvant immunotherapy in renal cell carcinoma. Annals of Oncology. 36(12). 1525–1534.

Sahu, Nisebita, Emily Chan, Felix Chu, et al.. (2017). Cotargeting of MEK and PDGFR/STAT3 Pathways to Treat Pancreatic Ductal Adenocarcinoma. Molecular Cancer Therapeutics. 16(9). 1729–1738. 26 indexed citations

Ryner, Lisa, Ameya Udyavar, Mélanie Desbois, et al.. (2017). Reactive stroma mediates CD8+ T cell spatial distribution and function in ovarian cancer. Annals of Oncology. 28. v349–v349. 1 indexed citations

Chung, Inhee, Mike Reichelt, Lily Shao, et al.. (2016). High cell-surface density of HER2 deforms cell membranes. Nature Communications. 7(1). 12742–12742. 57 indexed citations

Wilson, Timothy R., Yuanyuan Xiao, Jill M. Spoerke, et al.. (2014). Development of a robust RNA-based classifier to accurately determine ER, PR, and HER2 status in breast cancer clinical samples. Breast Cancer Research and Treatment. 148(2). 315–325. 21 indexed citations

Wilson, Catherine, Thinh Q. Pham, Xiaofen Ye, et al.. (2014). Abstract 693: AXL tyrosine kinase inhibition selectively sensitizes mesenchymal cancer cells to antimitotic agents. Cancer Research. 74(19_Supplement). 693–693. 1 indexed citations

Shames, David S., Kristi Elkins, Kimberly Walter, et al.. (2013). Loss of NAPRT1 Expression by Tumor-Specific Promoter Methylation Provides a Novel Predictive Biomarker for NAMPT Inhibitors. Clinical Cancer Research. 19(24). 6912–6923. 59 indexed citations

Spoerke, Jill M., Carol O’Brien, Ling Huw, et al.. (2012). Phosphoinositide 3-Kinase (PI3K) Pathway Alterations Are Associated with Histologic Subtypes and Are Predictive of Sensitivity to PI3K Inhibitors in Lung Cancer Preclinical Models. Clinical Cancer Research. 18(24). 6771–6783. 149 indexed citations

Jubb, Adrian M., Navneet Ratti, Laura A Strickland, et al.. (2012). Neuropilin‐2 expression in cancer. Histopathology. 61(3). 340–349. 29 indexed citations

10.

Jubb, Adrian M., et al.. (2011). Neuropilin‐1 expression in cancer and development. The Journal of Pathology. 226(1). 50–60. 162 indexed citations

11.

Moreno, Víctor, Richard D. Baird, Kinjal Shah, et al.. (2011). A phase I study evaluating GDC-0941, an oral phosphoinositide-3 kinase (PI3K) inhibitor, in patients with advanced solid tumors or multiple myeloma.. Journal of Clinical Oncology. 29(15_suppl). 3021–3021. 33 indexed citations

12.

Belvin, Marcia, Leanne Berry, Julie Chan, et al.. (2010). 132 Intermittent dosing of the MEK inhibitor, GDC-0973, and the PI3K inhibitor, GDC-0941, results in prolonged accumulation of Bim and causes strong tumor growth inhibition in vivo. European Journal of Cancer Supplements. 8(7). 48–48. 4 indexed citations

13.

Li, Wěi, Bu-Er Wang, Paul Moran, et al.. (2009). Pegylated Kunitz Domain Inhibitor Suppresses Hepsin-Mediated Invasive Tumor Growth and Metastasis. Cancer Research. 69(21). 8395–8402. 44 indexed citations

14.

Phillips, Gail D. Lewis, Guangmin Li, Debra L. Dugger, et al.. (2008). Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody–Cytotoxic Drug Conjugate. Cancer Research. 68(22). 9280–9290. 1259 indexed citations breakdown →

15.

Ingle, Gladys S., Pamela Chan, J. Michael Elliott, et al.. (2007). High CD21 expression inhibits internalization of anti‐CD19 antibodies and cytotoxicity of an anti‐CD19‐drug conjugate. British Journal of Haematology. 140(1). 46–58. 61 indexed citations

16.

Finkle, David, Vida Asghari, Elaine Mai, et al.. (2004). HER2-Targeted Therapy Reduces Incidence and Progression of Midlife Mammary Tumors in Female Murine Mammary Tumor Virus huHER2-Transgenic Mice. Clinical Cancer Research. 10(7). 2499–2511. 91 indexed citations

17.

Koeppen, Hartmut, Will Ince, Eric Holmgren, et al.. (2004). 150 Molecular tumor characteristics and response to bevacizumab plus irinotecan/5-fluorouracil/leucovorin in metastatic colorectal cancer. European Journal of Cancer Supplements. 2(8). 48–48. 2 indexed citations

18.

Chuntharapai, Anan, Katharine Grimmer, Kurt A. Schroeder, et al.. (2001). Isotype-Dependent Inhibition of Tumor Growth In Vivo by Monoclonal Antibodies to Death Receptor 4. The Journal of Immunology. 166(8). 4891–4898. 167 indexed citations

19.

Koeppen, Hartmut, et al.. (1993). Genetically Engineered Vaccines Comparison of Active versus Passive Immunotherapy against Solid Tumorsa. Annals of the New York Academy of Sciences. 690(1). 244–255. 5 indexed citations

20.

Teng, Michael N., et al.. (1991). Long-term inhibition of tumor growth by tumor necrosis factor in the absence of cachexia or T-cell immunity.. Proceedings of the National Academy of Sciences. 88(9). 3535–3539. 91 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact